Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.
Type:
Grant
Filed:
May 10, 2023
Date of Patent:
March 18, 2025
Assignee:
The Board of Regents of The University of Texas System
Abstract: Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
Type:
Grant
Filed:
February 1, 2023
Date of Patent:
March 18, 2025
Assignee:
Board of Regents, The University of Texas System
Inventors:
Philip Jones, Michael J. Soth, Jason P. Burke, Kang Le, Gang Liu
Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
Type:
Grant
Filed:
October 16, 2023
Date of Patent:
March 11, 2025
Assignee:
Board of Regents, The University of Texas System
Inventors:
Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Shelton S. Bradrick
Abstract: Methods and systems for assisting tonally-challenged singers. A microphone can be integrated with a sound reinforcement system used in a live performance. The microphone, which can transduce the performer's voice, can serve multiple purposes such as, for example, to feed input to the natural ear and to the sound reinforcement system. The processed sound of the performer's voice (with fundamental frequency emphasized) can be mixed into the signal fed to a stage “monitor” speaker facing the performer or a headset worn by the performer.
Type:
Grant
Filed:
August 9, 2021
Date of Patent:
March 11, 2025
Assignee:
Board of Regents, The University of Texas System
Inventors:
Eric A. Freudenthal, Eric M. Hanson, Bryan E. Usevitch
Abstract: A method of electrochemical sensing includes providing an electrochemical sensor comprising a glassy carbon substrate and gold nanoparticles located on a surface of the glassy carbon substrate; and sensing electrochemically a compound selected from the group consisting of polyfluoroalkyl compounds or perfluoroalkyl compounds using the electrochemical sensor. PFOA quantification was performed by Square Wave Adsorptive Cathodic Stripping Voltammetry (SW-AdCSV) in test solutions with a 100-5,000 ppt concentration. The concentration has a linear relationship with the stripping current within this range. Analysis of tap and groundwater samples performed by additions method demonstrated precision and accuracy above 95%. These electrodes show stability throughout 200 cycles, and reproducibility across similarly prepared but different electrodes above 97.5%.
Type:
Grant
Filed:
June 15, 2023
Date of Patent:
March 4, 2025
Assignees:
Board of Regents, The University of Texas System, Arizona Board of Regents on Behalf of Arizon State University
Inventors:
Dino Villagran, Paul Westerhoff, Jonathan Josue Calvillo Solis, Michael Wong
Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
Type:
Grant
Filed:
April 21, 2017
Date of Patent:
March 4, 2025
Assignees:
Astrocyte Pharmaceuticals, Inc., Board of Regents, The University of Texas System, The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors:
William S. Korinek, James D. Lechleiter, Theodore E. Liston, Kenneth A. Jacobson
Abstract: Embodiments can take brain activity measurement and decode into continuous language. Embodiment can use non-invasive brain recordings, such as functional magnetic resonance imaging (fMRI) and functional near-infrared spectroscopy (fNIRS) to detect changes in blood oxygen level that are coupled to neural activity. These brain recordings can be used by a language reconstruction model that involves a neural language model to predict a next word in a sequence and an encoding model to decode the recordings into continuous language, or sequences of words.
Type:
Application
Filed:
February 22, 2023
Publication date:
February 27, 2025
Applicant:
Board of Regents, The University of Texas System
Abstract: In some aspects, the present disclosure provides a nanoparticle composition comprising tRNA and an aminolipid delivery compound. The aminolipid delivery compound may be a dendrimer, dendron, or dendritic lipid, a polymer such as a polyamide or polyester, or a lipid with one or more hydrophobic components. In some embodiments, these compositions may be administered to a patient to treat a genetic disease or disorder such as cystic fibrosis, Duchene muscular dystrophy, or cancer.
Type:
Application
Filed:
October 29, 2024
Publication date:
February 27, 2025
Applicant:
The Board of Regents of The University of Texas System
Inventors:
Daniel J. SIEGWART, Philip J. THOMAS, Arthur E. JOHNSON, Michael J. TORRES, Jason B. MILLER
Abstract: Described herein are methods and systems for identifying and/or treating subjects having cancer who are more likely to respond to treatment with an inhibitor of the transcription factor HIF-2?.
Type:
Grant
Filed:
March 19, 2021
Date of Patent:
February 25, 2025
Assignee:
The Board of Regents of The University of Texas System
Inventors:
Min Soo Kim, James Brugarolas, Tae Hyun Hwang, Yang Xie
Abstract: The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.
Type:
Application
Filed:
November 4, 2024
Publication date:
February 20, 2025
Applicant:
Board of Regents, The University of Texas System
Inventors:
Michael A. CURRAN, Ashvin R. JAISWAL, Dongxing ZHA, Carlo TONIATTI, Bianka PRINZ, Nadthakarn BOLAND, Eric KRAULAND
Abstract: The invention relates generally to an allele on human chromosome 9 associated with increased risk for coronary heart disease and the use or detection of such an allele in determining whether a human has an increased risk for coronary heart disease. In one aspect, the invention relates to methods for detecting a predisposition or propensity or susceptibility for coronary heart disease in a human, comprising detecting the presence of an allele on human chromosome 9 that is associated with an increased risk for coronary heart disease in a human. Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has an RA-CHR9 allele, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP). The invention also relates to kits for detecting the presence of an allele on chromosome 9 associated with an increased risk for coronary heart disease.
Type:
Grant
Filed:
September 13, 2021
Date of Patent:
February 18, 2025
Assignee:
Board of Regents, The University of Texas System
Abstract: In one aspect, a neuromodulation device is described herein. In some embodiments, a neuromodulation device comprises a chamber operable to receive a nerve, at least one electrode disposed in the chamber, and a channel defined by two walls. In some embodiments, the channel of the device is in fluid communication with an interior of the chamber and an external surface of the device. In another aspect, methods of neuromodulation are described herein. In some embodiments, methods described herein can use one or more neuromodulation devices described herein.
Type:
Grant
Filed:
November 9, 2018
Date of Patent:
February 18, 2025
Assignee:
Board of Regents, The University of Texas System
Inventors:
Mario I. Romero-Ortega, Stuart F. Cogan, Aswini Kanneganti
Abstract: A method and system for detecting and analyzing internet traffic from Internet of Things (IoT) devices is presented. A network telescope is employed to collect unsolicited data packets. The data packets are analyzed to determine whether they arise from a misconfigured device or from a malicious device (darknet sanitization) or from some other source. Traffic from misconfigured devices is filtered out. The data packets from malicious devices are analyzed and a classification model is trained to classify the data packets into originating from an IoT or from a non-IoT device. The classifier is then validated on a separate set of data. The data packets originating from malicious IoT devices are further analyzed by such techniques a clustering (e.g. agglomerative hierarchical clustering), geo-location analysis, methods of attack, and coordination of attacks.
Type:
Grant
Filed:
April 11, 2022
Date of Patent:
February 4, 2025
Assignee:
Board of Regents, The University of Texas System
Abstract: The present invention includes compositions and methods of for treating plants infected with fungal pathogens by contacting an infected plant or plant at risk of infection with a fungicidal composition comprising an fungicide selected from copper compound such as copper octanoate or copper hydroxide, or a triazole fungicide such as myclobutanil, propionazole, tebuconazole or epoxiconazole, an enhancer selected from apyrase inhibitors, e.g., N-(m-tolyl)-[1,1?-biphenyl]-4-sulfonamide, S-heptyl 2-oxo-2H-chromene 3-carbothioate, 3-(N-(4-bromophenyl) sulfamoyl)-N-(3-nitrophenyl)benzamide, or (E)-3-methyl-N-(1-(naphthalen-2-yl) ethylidene)benzohydrazide and, optionally, a phytologically-acceptable inert carrier.
Type:
Grant
Filed:
August 20, 2021
Date of Patent:
February 4, 2025
Assignees:
Board of Regents, The University of Texas System, Cottongen, LLC
Inventors:
Stanley J. Roux, Gregory B. Clark, Simon L. Hiebert
Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
Type:
Grant
Filed:
October 12, 2021
Date of Patent:
January 28, 2025
Assignees:
Board of Regents, The University of Texas System, Oregon State University
Abstract: Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.
Type:
Grant
Filed:
July 24, 2020
Date of Patent:
January 21, 2025
Assignee:
The Board of Regents, The University of Texas System
Inventors:
Burton Dickey, Michael Tuvim, Scott Evans
Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
Type:
Grant
Filed:
February 23, 2021
Date of Patent:
January 21, 2025
Assignees:
Board of Regents, The University of Texas System, Duke University, Case Western Reserve, The Regents of the University of California
Inventors:
Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Simon G. Gregory, Farren B. S. Briggs, Lisa F. Barcellos, Shelton S. Bradrick, Irina Evsyukova, Dennis C. Ko
Abstract: The present invention provides targeting probe, imaging probes, and probes for use as a medicament to treat damaged cartilage, where the probe targets injured tissue and can then be imaged and/or release agents to trigger the migration of surrounding chondrocytes from healthy tissue to injured tissue and/or recruit synovial stem cells.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
January 21, 2025
Assignees:
Board of Regents, The University of Texas System